A Study Called ARAMON to Learn to What Extent Does Study Treatment With Darolutamide Affects Testosterone Levels in Men With Prostate Cancer That Had Not Been Treated With Hormonal Therapy Compared to Treatment With Enzalutamide

PHASE2CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

December 19, 2022

Primary Completion Date

August 20, 2024

Study Completion Date

December 4, 2024

Conditions
Biochemically Recurrent Prostate Cancer
Interventions
DRUG

Darolutamide(BAY1841788, Nubeqa)

tablet, oral

DRUG

Enzalutamide

tablet, oral

Trial Locations (5)

10065

Memorial Sloan Kettering Cancer Center New York - Main Campus, New York

43230

Central Ohio Urology Group - Gahanna, Gahanna

91411

Unio Specialty Care - Urology - Sherman Oaks, Sherman Oaks

02114-2696

Mass General Cancer Center, Boston

02215

Beth Israel Deaconess Medical Center - Oncology, Boston

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Bayer

INDUSTRY